首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

2028272

CAR-T細胞療法市場規模、佔有率、成長及全球產業分析：按類型和應用分類，區域的洞察，2026-2034年的預測

CAR-T Cell Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

出版日期: 2026年03月30日 | 出版商:

Fortune Business Insights Pvt. Ltd. | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

CAR-T細胞療法市場的成長要素

受癌症發病率上升、免疫療法快速發展以及個人化醫療投資增加的推動，全球CAR-T細胞療法市場正經歷強勁成長。 CAR-T（嵌合體抗原受體T細胞）療法是一種突破性的癌症治療方法改造患者自身的T細胞，使其能夠識別並摧毀癌細胞，為骨髓惡性腫瘤提供靶向且持久的治療效果。

市場規模及預測

根據行業資料：

2025年市場規模：89.5億美元
2026年市場規模：109.2億美元
2034年市場預測：192.5億美元
年複合成長率（2026-2034年）：7.34%

2025年至2034年間，市場規模幾乎加倍，這強烈反映了 CAR-T 療法在腫瘤治療途徑中的長期廣泛應用。

區域市場概覽

北美（市場領導）

2025年市場規模：63億美元
2026年市場規模：77.3億美元
2025年市場佔有率：全球市場的70.41%

北美憑藉其先進的醫療基礎設施、完善的保險償付體系、較高的癌症發病率以及對創新治療方法的早期應用，正引領著CAR-T細胞療法市場的發展。美國仍然是該地區的主要收入來源。

歐洲

2025年市場規模：16.7億美元
2026年市場規模：20.1億美元
2025年市場佔有率：18.67%

在歐洲，在政府資助、臨床研究計畫和越來越多的CAR-T 產品監管核准的支持下，CAR-T 產業正穩步成長。

亞太地區（成長最快的地區）

2025年市場規模：8億美元
2026年市場規模：9.9億美元
2025年市場佔有率：8.94%

由於癌症患者人數不斷增加、臨床試驗規模擴大以及中國、日本和印度等國家醫療保健投資增加，預計亞太地區將紀錄最高的成長率。

世界其他地區

2025年市場規模：1.7億美元
2026年市場規模：2億美元
2025年市場佔有率：1.97%

該地區的成長得益於醫療基礎設施的改善和癌症治療服務覆蓋範圍的逐步擴大。

市場促進因素

CAR-T細胞療法市場主要受以下幾個關鍵因素驅動：

在全球範圍內，白血病、淋巴瘤和多發性骨髓瘤等血液癌症的發生率上升。
FDA和EMA等監管機構核准的CAR-T療法數量增加。
擴大臨床試驗規模（～2023年，在研候選藥物超過440種）
基因編輯技術（例如 CRISPR）的進步
擴大患者支持計劃和醫療保健意識活動
生技公司與製藥公司之間合作日益加強

市場趨勢

影響該產業發展的主要趨勢包括以下幾點：

過渡到同種異體（現成）CAR-T療法可提高可擴展性並縮短治療時間。
擴大研發夥伴關係（例如，BioNTech和Autolus的合作關係）
臨床研發管線和實驗性CAR-T療法的快速擴展
人們越來越關注血液癌症以外的多種疾病的治療。

市場限制因素

儘管市場成長強勁，仍面臨以下挑戰：

治療費用高昂，每位患者的費用從 37.3萬美元到超過 100萬美元不等。
由於治療標準嚴格，只有有限數量的患者合格。
複雜的製造程序和個人化的生產流程
新興國家對保險償付的支持不足。

這些因素限制了這種療法的廣泛應用，尤其是在中低收入國家。

細分概覽

藥物類型：Axicabtagene ciloleucel (Yescarta) 在市場上佔據領先地位。
適應症細分：非何傑金氏淋巴瘤佔市場佔有率的65%以上，是推動市場成長的主要因素。
依最終用戶分類：由於治療需求複雜，醫院佔最大佔有率。

市場分析、洞察與預測：依藥物類型分類
- Axicabtagene Ciloleucel (Yescarta)
- Brexucabtagene Autoleucel (Tecartus)
- Ciltacabtagene Autoleucel (Carvykti)
- Idecabtagene Vicleucel (Abecma)
- Lisocabtagene Maraleucel (Breyanzi)
- Tisagenlecleucel (Kymriah)
- 其他
市場分析、洞察與預測：依適應症分類。
- 急性淋巴性白血病
- 非何傑金氏淋巴瘤
- 多發性骨髓瘤
市場分析、洞察與預測：依最終用戶分類
- 醫院
- 腫瘤治療中心
市場分析、洞察與預測：依地區分類
- 北美洲
- 歐洲
- 亞太地區
- 世界其他地區

第6章北美CAR-T細胞療法市場分析、洞察與預測（2021-2034年）

國家
- 美國
- 加拿大

第7章歐洲CAR-T細胞療法市場分析、洞察與預測（2021-2034年）

國家
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 斯堪地那維亞
- 其他歐洲國家

第8章亞太地區CAR-T細胞療法市場分析、洞察與預測（2021-2034年）

國家
- 中國
- 日本
- 印度
- 澳洲
- 東南亞
- 其他亞太國家

第9章 2021-2034年其他地區CAR-T細胞療法全球市場分析、洞察與預測

第10章競爭分析

全球市場佔有率分析（2025年）
公司簡介
- Gilead Sciences, Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.（Janssen Global Services, LLC）
- Caribou Biosciences, Inc.
- CARsgenTherapeutics Co., Ltd
- JW Therapeutics（Shanghai）Co., Ltd.
- Cartesian Therapeutics, Inc.
- Aurora Biopharma

簡介目錄圖表

Product Code: FBI108455

Growth Factors of CAR-T cell therapy Market

The global CAR-T cell therapy market is experiencing strong expansion due to rising cancer prevalence, rapid advancements in immunotherapy, and increasing investment in personalized medicine. CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of cancer treatment that modifies a patient's T-cells to recognize and destroy cancer cells, offering targeted and durable responses in hematologic malignancies.

Market Size and Forecast

According to the industry data:

2025 Market Size: USD 8.95 billion
2026 Market Size: USD 10.92 billion
2034 Market Forecast: USD 19.25 billion
CAGR (2026-2034): 7.34%

The market is expected to nearly double between 2025 and 2034, reflecting strong long-term adoption of CAR-T therapies in oncology treatment pathways.

Regional Market Overview

North America (Market Leader)

2025 Value: USD 6.3 billion
2026 Value: USD 7.73 billion
Share in 2025: 70.41% of global market

North America dominates the CAR-T cell therapy market due to advanced healthcare infrastructure, strong reimbursement systems, high cancer incidence, and early adoption of innovative therapies. The United States remains the key revenue generator in this region.

Europe

2025 Value: USD 1.67 billion
2026 Value: USD 2.01 billion
Share in 2025: 18.67%

Europe shows steady growth supported by government funding, clinical research programs, and increasing regulatory approvals for CAR-T products.

Asia Pacific (Fastest Growing Region)

2025 Value: USD 0.80 billion
2026 Value: USD 0.99 billion
Share in 2025: 8.94%

Asia Pacific is expected to record the highest growth rate due to rising cancer cases, expanding clinical trials, and increasing healthcare investments in countries like China, Japan, and India.

Rest of the World

2025 Value: USD 0.17 billion
2026 Value: USD 0.20 billion
Share in 2025: 1.97%

Growth in this region is supported by improving healthcare infrastructure and gradual expansion of oncology treatment access.

Market Drivers

The CAR-T cell therapy market is driven by several key factors:

Rising global incidence of hematologic cancers such as leukemia, lymphoma, and multiple myeloma
Increasing approvals of CAR-T therapies by regulatory bodies like the FDA and EMA
Expansion of clinical trials, with over 440 pipeline candidates in 2023
Advancements in gene editing technologies such as CRISPR
Growth in patient assistance programs and healthcare awareness initiatives
Increasing collaborations between biotech and pharmaceutical companies

Market Trends

Major trends shaping the industry include:

Shift toward allogeneic (off-the-shelf) CAR-T therapies, improving scalability and reducing treatment time
Expansion of R&D partnerships (e.g., BioNTech-Autolus collaborations)
Rapid growth in clinical pipeline and experimental CAR-T therapies
Increasing focus on treating multiple indications beyond blood cancers

Market Restraints

Despite strong growth, the market faces challenges:

High treatment cost ranging from USD 373,000 to over USD 1 million per patient
Limited patient eligibility due to strict treatment conditions
Complex manufacturing and personalized production processes
Lack of reimbursement support in emerging economies

These factors restrict widespread adoption, particularly in low- and middle-income countries.

Segmentation Overview

By Drug Type: Axicabtagene ciloleucel (Yescarta) leads the market
By Indication: Non-Hodgkin lymphoma dominates with over 65% share
By End User: Hospitals hold the largest share due to complex treatment requirements

Competitive Landscape

Key players include:

Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
Johnson & Johnson (Janssen)
Caribou Biosciences, Inc.
JW Therapeutics
CARsgen Therapeutics

Gilead Sciences leads the market primarily through strong sales of Yescarta, while Bristol-Myers Squibb continues expanding its CAR-T pipeline globally.

Conclusion

The global CAR-T cell therapy market is on a strong growth trajectory, projected to increase from USD 8.95 billion in 2025 to USD 10.92 billion in 2026, and further reach USD 19.25 billion by 2034. Driven by rising cancer burden, technological advancements, and expanding clinical applications, CAR-T therapy is expected to become a cornerstone of next-generation oncology treatment despite challenges related to cost and accessibility.

Segmentation By Drug Type

Axicabtagene Ciloleucel (Yescarta)
Brexucabtagene Autoleucel (Tecartus)
Ciltacabtagene Autoleucel (Carvykti)
Idecabtagene Vicleucel (Abecma)
Lisocabtagene Maraleucel (Breyanzi)
Tisagenlecleucel (Kymriah)
Others

By Indication

Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma

By End-user

Hospitals
Oncology Treatment Centers

By Region

North America (By Drug Type, By Indication, By End-user, By Country)
- U.S.
- Canada
Europe (By Drug Type, By Indication, By End-user, By Country/Sub-region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Drug Type, By Indication, By End-user, By Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Rest of the World (By Drug Type, By Indication, By End-user)

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Prevalence of Chronic Diseases, by Key Countries/Regions, 2025/2025
4.2. Pipeline Analysis, By Key Players
4.3. Technological Advancements
4.4. New Product Launches, By Key Players
4.5. Key Industry Developments: Mergers, Acquisitions & Partnerships
4.6. Impact of COVID-19 on the Market

5. Global CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Drug Type
- 5.1.1. Axicabtagene Ciloleucel (Yescarta)
- 5.1.2. Brexucabtagene Autoleucel (Tecartus)
- 5.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 5.1.4. Idecabtagene Vicleucel (Abecma)
- 5.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 5.1.6. Tisagenlecleucel (Kymriah)
- 5.1.7. Others
5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. Acute lymphoblastic leukemia
- 5.2.2. Non-Hodgkin lymphoma
- 5.2.3. Multiple Myeloma
5.3. Market Analysis, Insights and Forecast - By End User
- 5.3.1. Hospitals
- 5.3.2. Oncology Treatment Centers
5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World

6. North America CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Drug Type
- 6.1.1. Axicabtagene Ciloleucel (Yescarta)
- 6.1.2. Brexucabtagene Autoleucel (Tecartus)
- 6.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 6.1.4. Idecabtagene Vicleucel (Abecma)
- 6.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 6.1.6. Tisagenlecleucel (Kymriah)
- 6.1.7. Others
6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. Acute lymphoblastic leukemia
- 6.2.2. Non-Hodgkin lymphoma
- 6.2.3. Multiple Myeloma
6.3. Market Analysis, Insights and Forecast - By End User
- 6.3.1. Hospitals
- 6.3.2. Oncology Treatment Centers
6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada

7. Europe CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Drug Type
- 7.1.1. Axicabtagene Ciloleucel (Yescarta)
- 7.1.2. Brexucabtagene Autoleucel (Tecartus)
- 7.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 7.1.4. Idecabtagene Vicleucel (Abecma)
- 7.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 7.1.6. Tisagenlecleucel (Kymriah)
- 7.1.7. Others
7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. Acute lymphoblastic leukemia
- 7.2.2. Non-Hodgkin lymphoma
- 7.2.3. Multiple Myeloma
7.3. Market Analysis, Insights and Forecast - By End User
- 7.3.1. Hospitals
- 7.3.2. Oncology Treatment Centers
7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe

8. Asia Pacific CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Drug Type
- 8.1.1. Axicabtagene Ciloleucel (Yescarta)
- 8.1.2. Brexucabtagene Autoleucel (Tecartus)
- 8.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 8.1.4. Idecabtagene Vicleucel (Abecma)
- 8.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 8.1.6. Tisagenlecleucel (Kymriah)
- 8.1.7. Others
8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. Acute lymphoblastic leukemia
- 8.2.2. Non-Hodgkin lymphoma
- 8.2.3. Multiple Myeloma
8.3. Market Analysis, Insights and Forecast - By End User
- 8.3.1. Hospitals
- 8.3.2. Oncology Treatment Centers
8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific

9. Rest of the World CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Drug Type
- 9.1.1. Axicabtagene Ciloleucel (Yescarta)
- 9.1.2. Brexucabtagene Autoleucel (Tecartus)
- 9.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 9.1.4. Idecabtagene Vicleucel (Abecma)
- 9.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 9.1.6. Tisagenlecleucel (Kymriah)
- 9.1.7. Others
9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. Acute lymphoblastic leukemia
- 9.2.2. Non-Hodgkin lymphoma
- 9.2.3. Multiple Myeloma
9.3. Market Analysis, Insights and Forecast - By End User
- 9.3.1. Hospitals
- 9.3.2. Oncology Treatment Centers

10. Competitive Analysis

10.1. Global Market Share Analysis (2025)
10.2. Company Profiles
- 10.2.1. Gilead Sciences, Inc.
  - 10.2.1.1. Overview
  - 10.2.1.2. Products & Services
  - 10.2.1.3. SWOT Analysis
  - 10.2.1.4. Recent Developments
  - 10.2.1.5. Strategies
  - 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Novartis AG
  - 10.2.2.1. Overview
  - 10.2.2.2. Products & Services
  - 10.2.2.3. SWOT Analysis
  - 10.2.2.4. Recent Developments
  - 10.2.2.5. Strategies
  - 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Bristol-Myers Squibb Company
  - 10.2.3.1. Overview
  - 10.2.3.2. Products & Services
  - 10.2.3.3. SWOT Analysis
  - 10.2.3.4. Recent Developments
  - 10.2.3.5. Strategies
  - 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
  - 10.2.4.1. Overview
  - 10.2.4.2. Products & Services
  - 10.2.4.3. SWOT Analysis
  - 10.2.4.4. Recent Developments
  - 10.2.4.5. Strategies
  - 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Caribou Biosciences, Inc.
  - 10.2.5.1. Overview
  - 10.2.5.2. Products & Services
  - 10.2.5.3. SWOT Analysis
  - 10.2.5.4. Recent Developments
  - 10.2.5.5. Strategies
  - 10.2.5.6. Financials (Based on Availability)
- 10.2.6. CARsgenTherapeutics Co., Ltd
  - 10.2.6.1. Overview
  - 10.2.6.2. Products & Services
  - 10.2.6.3. SWOT Analysis
  - 10.2.6.4. Recent Developments
  - 10.2.6.5. Strategies
  - 10.2.6.6. Financials (Based on Availability)
- 10.2.7. JW Therapeutics (Shanghai) Co., Ltd.
  - 10.2.7.1. Overview
  - 10.2.7.2. Products & Services
  - 10.2.7.3. SWOT Analysis
  - 10.2.7.4. Recent Developments
  - 10.2.7.5. Strategies
  - 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Cartesian Therapeutics, Inc.
  - 10.2.8.1. Overview
  - 10.2.8.2. Products & Services
  - 10.2.8.3. SWOT Analysis
  - 10.2.8.4. Recent Developments
  - 10.2.8.5. Strategies
  - 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Aurora Biopharma
  - 10.2.9.1. Overview
  - 10.2.9.2. Products & Services
  - 10.2.9.3. SWOT Analysis
  - 10.2.9.4. Recent Developments
  - 10.2.9.5. Strategies
  - 10.2.9.6. Financials (Based on Availability)

簡介目錄圖表

List of Tables

Table 1: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
Table 2: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
Table 3: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
Table 4: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Region, 2021-2034
Table 5: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
Table 6: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
Table 7: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
Table 8: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 9: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
Table 10: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
Table 11: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
Table 12: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
Table 13: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
Table 14: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
Table 15: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
Table 16: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
Table 17: Rest of the World CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
Table 18: Rest of the World CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
Table 19: Rest of the World CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034

List of Figures

Figure 1: Global CAR-T Cell Therapy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
Figure 2: Global CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025 & 2034
Figure 3: Global CAR-T Cell Therapy Market Value Share (%), By Indication, 2025 & 2034
Figure 4: Global CAR-T Cell Therapy Market Value Share (%), By End User, 2025 & 2034
Figure 5: Global CAR-T Cell Therapy Market Value Share (%), By Region, 2025 & 2034
Figure 6: North America CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
Figure 7: North America CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
Figure 8: North America CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
Figure 9: North America CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
Figure 10: North America CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
Figure 11: North America CAR-T Cell Therapy Market Value Share (%), By End User, 2025
Figure 12: North America CAR-T Cell Therapy Market Value (USD billion), by Country, 2025 & 2034
Figure 13: North America CAR-T Cell Therapy Market Value Share (%), by Country, 2025
Figure 14: Europe CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
Figure 15: Europe CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
Figure 16: Europe CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
Figure 17: Europe CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
Figure 18: Europe CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
Figure 19: Europe CAR-T Cell Therapy Market Value Share (%), By End User, 2025
Figure 20: Europe CAR-T Cell Therapy Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
Figure 21: Europe CAR-T Cell Therapy Market Value Share (%), by Country/ Sub-Region, 2025
Figure 22: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
Figure 23: Asia Pacific CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
Figure 24: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
Figure 25: Asia Pacific CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
Figure 26: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
Figure 27: Asia Pacific CAR-T Cell Therapy Market Value Share (%), By End User, 2025
Figure 28: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
Figure 29: Asia Pacific CAR-T Cell Therapy Market Value Share (%), by Country/ Sub-Region, 2025
Figure 30: Rest of the World CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
Figure 31: Rest of the World CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
Figure 32: Rest of the World CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
Figure 33: Rest of the World CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
Figure 34: Rest of the World CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
Figure 35: Rest of the World CAR-T Cell Therapy Market Value Share (%), By End User, 2025
Figure 36: Global CAR-T Cell Therapy Market Share (%), By Company, 2025